System Certification ISO 9001:2000
Exbio Antibodies CZ / SK eShop
by categories | a-z list | Application type: Flow Cytometry | Immunohistochemistry | Functional Studies

Mouse Monoclonal to CD266 / TWEAK R

ITEM-4 (IgG2b)

Technical Information Request    Inquiry for Bulk Prices

Product No. Form Quantity Stock Price Datasheet Shop
  11-755-C025 purified 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  11-755-C100 purified 0.1 mg yes choose region PDF datasheetHTML datasheet buy
  12-755-C100 low endotoxin 0.1 mg yes choose region PDF datasheetHTML datasheet buy
  1P-755-C025 PE 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  1P-755-C100 PE 0.1 mg yes choose region PDF datasheetHTML datasheet buy
- In stock! Ready for immediate despatch - Manufacture on order


CD266 / TWEAK R (TNFRSF12A), also known as FN14 (fibroblast growth factor-inducible 14) is a receptor for CD255 / TWEAK, the TNF-like weak inducer of apoptosis. CD266 is expressed on endothelial cells, as well as on some cancer tissues, and plays a role in CD255-induced endothelial cell migration, proliferation, and angiogenesis. The CD255-CD266 interaction, or antibody-mediated triggering of CD266 is also able to induce apoptosis and necrosis in CD266-positive cells (including tumor cells), which might have therapeutic potential.


The mouse monoclonal antibody ITEM-4 recognizes CD266 / TWEAK R, a TNFR superfamily receptor for CD255 / TWEAK, a TNF-like weak inducer of apoptosis.

Regulatory Status


human CD266-transfected P815 cells

Species Reactivity:

  • Human
  • Mouse

Negative Species:


  • Flow Cytometry
  • Western Blotting
  • Immunohistochemistry (frozen sections)
  • Functional Application
Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

Product Specific References

  • *Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H: Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol. 2003 Jan 1;170(1):341-8. [Abstract] [Full Text]
  • *Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K, Yagita H, Nakajima Y: Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp Ther Med. 2011 Jan;2(1):103-108 [Abstract] [Full Text]
  • *Sanz AB, Sanchez-Niño MD, Carrasco S, Manzarbeitia F, Ruiz-Andres O, Selgas R, Ruiz-Ortega M, Gonzalez-Enguita C, Egido J, Ortiz A: Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells. PLoS One. 2012;7(10):e47440. [Abstract] [Full Text]
  • *Roos C, Wicovsky A, Müller N, Salzmann S, Rosenthal T, Kalthoff H, Trauzold A, Seher A, Henkler F, Kneitz C, Wajant H: Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. J Immunol. 2010 Aug 1;185(3):1593-605. [Abstract] [Full Text]
  • For research use only. Not for drug, diagnostic or other use.

    Example Data

    ITEM-4 PE

    Fig. 1. Surface staining of CD266-transfected L51784 cells with anti-human CD266 (ITEM-4) PE.

    Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO´s term and conditions which are available at
    © 2003 EXBIO. All rights reserved.
    terms and conditions | privacy policy